StockNews.com upgraded shares of Lipocine (NASDAQ:LPCN – Free Report) from a hold rating to a buy rating in a research report released on Monday morning.
Separately, Alliance Global Partners initiated coverage on shares of Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 price objective for the company.
Check Out Our Latest Stock Analysis on Lipocine
Lipocine Price Performance
Lipocine (NASDAQ:LPCN – Get Free Report) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) EPS for the quarter. The business had revenue of $0.09 million during the quarter. On average, equities analysts anticipate that Lipocine will post -0.92 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP purchased a new position in Lipocine Inc. (NASDAQ:LPCN – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent reporting period. 9.11% of the stock is currently owned by institutional investors and hedge funds.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Featured Stories
- Five stocks we like better than Lipocine
- The Basics of Support and Resistance
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What Are the FAANG Stocks and Are They Good Investments?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Insider Trades May Not Tell You What You Think
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.